Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis
Authors:
- C.M. PflugerCPC.M. Pfluger
- R.D. HendersonRHR.D. Henderson
- P.A. McCombePMP.A. McCombe
- 1 August 2012
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 249 (1-2) , 93-95
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council of Australia
- Motor Neurone Disease Research Institute of Australia
This publication has 26 references indexed in Scilit:
- Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patientsClinical Immunology, 2012
- Insights into the initiation of type 2 immune responsesImmunology, 2011
- Production and functions of IL-33 in the central nervous systemBrain Research, 2011
- Measurement of Interleukin-33 (IL-33) and IL-33 Receptors (sST2 and ST2L) in Patients with Rheumatoid ArthritisJournal of Korean Medical Science, 2011
- Role of IL-33 in inflammation and diseaseJournal of Inflammation, 2011
- Toll/Interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunctionCardiovascular Diabetology, 2011
- The enigmatic processing and secretion of interleukin-33Cellular & Molecular Immunology, 2010
- Induction of IL-33 expression and activity in central nervous system gliaJournal of Leukocyte Biology, 2008
- Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosisNature Neuroscience, 2008
- IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factorin vivoProceedings of the National Academy of Sciences, 2007